Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute Lymphoblastic Leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    555 result(s) found for: Acute Lymphoblastic Leukemia. Displaying page 5 of 28.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004773-27 Sponsor Protocol Number: AALL08B1 Start Date*: 2014-03-07
    Sponsor Name:Children's Oncology Group
    Full Title: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006541-14 Sponsor Protocol Number: ema3_pegAML Start Date*: 2007-07-27
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: A phase II pilot trial to evaluate the efficacy of treatment with Pegilate G-CSF in a group of elderly patients AML without chemotherapy indications
    Medical condition: acute mieloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005248-26 Sponsor Protocol Number: AML 07 Start Date*: 2008-05-29
    Sponsor Name:AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA
    Full Title: INDUCTION, CONSOLIDATION AND INTENSIFICATION PROTOCOL FOR PATIENTS YOUNGER THAN 66 YEARS WITH PREVIOUSLY UNTREATED CD33 POSITIVE ACUTE MYELOID LEUKEMIA (AML)
    Medical condition: newly diagnosed (untreated) and CD 33 positive AML, under 66 years.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002983-32 Sponsor Protocol Number: CLBH589B2213 Start Date*: 2009-06-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
    Medical condition: Patients with refractory de novo or secondary acute myelogenous leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024264-18 Sponsor Protocol Number: MT103-205 Start Date*: 2011-11-23
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati...
    Medical condition: Pediatric and adolescent patients with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) IT (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001588-78 Sponsor Protocol Number: SPON CU 125 Start Date*: 2005-06-13
    Sponsor Name:Cardiff University
    Full Title: AML16 Pilot Trial: A Phase1/2 Trial to assess the feasibility of combining Clofarabine with daunorubicin and Daunorubicin + Clofarabine with Mylotarg in older patients with Acute Myeloid Leukaemia ...
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000880 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001082-15 Sponsor Protocol Number: IPC2006-07 Start Date*: 2008-07-31
    Sponsor Name:Institut Paoli Calmette
    Full Title: Etude de Phase I-II multicentrique de l'association Cloretazine-Daunorubicine-Aracytine dans le traitement des leucémies aigües myéloïdes du groupe cytogénétique défavorable.
    Medical condition: Malades atteints de Leucémie Aigüe Myéloïde
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024346 Leukemia myeloblastic acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004710-41 Sponsor Protocol Number: AMLBFM0401 Start Date*: 2006-11-26
    Sponsor Name:St. Anna Kinderkrebsforschung
    Full Title: Multizentrische Therapieoptimierungsstudie AML-BFM 2004 zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen Multicentric therapy optimizing study AML-BFM 2004 for the trea...
    Medical condition: For acute myeloic leukaemia in children and juveniles improvment of treatment with new medications should be investigated: 1. Cladribine: originally licenced for hairy cell leukamia has shown good ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001941 AML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006475-36 Sponsor Protocol Number: RG_07-187 Start Date*: 2008-08-13
    Sponsor Name:University of Birmingham
    Full Title: Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia
    Medical condition: Patients who have Acute Myeloid Leukaemia (AML) will be recruited to this trial.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004836-39 Sponsor Protocol Number: Initial-1 Start Date*: 2017-11-01
    Sponsor Name: Goethe Universität
    Full Title: An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy I...
    Medical condition: Acute lymphoblastic leukemia, Philadelphia-chromosome and BCR-ABL negative disease, patient aged 56 years or older
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001347-37 Sponsor Protocol Number: GIMEMAAML17(EORTC06012) Start Date*: 2004-07-30
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untre...
    Medical condition: Previously untreated primary or secondary AML (including AML after MDS).All FAB subtypes except M3.No AML supervening after other myeloproliferative diseases.Age 61-75 years.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004356-39 Sponsor Protocol Number: GIMEMAAML19(EORTC06031) Start Date*: 2005-05-16
    Sponsor Name:E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
    Full Title: Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III tr...
    Medical condition: Elderly patients (61-75 years not eligible for intensive chemotherapy;age > 75 years), with previously untreated, primary or secondary (no after other myeloproliferative diseases) AML (except M3).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020432-18 Sponsor Protocol Number: LAMAN-01AN Start Date*: 2011-05-03
    Sponsor Name:ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA
    Full Title: TRATAMIENTO DE MANTENIMIENTO CON 5-AZACITIDINA EN PACIENTES CON LEUCEMIA MIELOBLÁSTICA AGUDA NO ELEGIBLES PARA TRATAMIENTO INTENSIVO Y CON RESPUESTA PARCIAL O COMPLETA TRAS QUIMIOTERAPIA DE INDUCCIÓN
    Medical condition: PACIENTES CON LEUCEMIA MIELOBLÁSTICA AGUDA NO ELEGIBLES PARA TRATAMIENTO INTENSIVO Y CON RESPUESTA PARCIAL O COMPLETA TRAS QUIMIOTERAPIA DE INDUCCIÓN
    Disease: Version SOC Term Classification Code Term Level
    13 10024346 Leucemia mieloblástica aguda LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001430-14 Sponsor Protocol Number: peg-filgrastim Vs filgrastim nel t Start Date*: 2007-02-19
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Peg-filgrastim Vs filgrastrim in pediatric patients.
    Medical condition: haematologic malignant tumors
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000880 PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004968-40 Sponsor Protocol Number: TUD-SORAML-034 Start Date*: 2009-02-20
    Sponsor Name:Technische Universität Dresden
    Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Medical condition: Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10001941 AML LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003581-34 Sponsor Protocol Number: DASATINIB compassionate use Start Date*: 2006-07-27
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: DASATINIB compassionate use
    Medical condition: CML and Ph
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000880 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000766-30 Sponsor Protocol Number: HO146 Start Date*: 2018-03-09
    Sponsor Name:HOVON Foundation
    Full Title: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.
    Medical condition: Precursor B-acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006978-20 Sponsor Protocol Number: HBS407 Start Date*: 2007-11-21
    Sponsor Name:Talon Therapeutics , Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic...
    Medical condition: Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000706-36 Sponsor Protocol Number: 20120216 Start Date*: 2013-12-10
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic ...
    Medical condition: Adult patients with relapsed and/or refractory Philadelphia Chromosome- positive B-precursor ALL
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    16.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018314-75 Sponsor Protocol Number: MT103-203 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor...
    Medical condition: minimal residual disease (MRD) of B-precursor ALL
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 08:13:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA